Personal tools

Sponsorname

Your company could advertise here

www.fla-consulting.eu

Glossary:TAG-00019-Pri-Prü

From GxPlex

Revision as of 13:50, 16 July 2026 by Gxplex admin (talk | contribs) (1 revision imported)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search


Glossary > Principal investigator

Principal investigator
Tag-ID TAG-00019-Pri-Prü
English Principal investigator / Lead investigator / Coordinating investigator
EN Abbr. PI
French Investigateur principal / Investigatrice principale / Investigateur coordinateur / Investigatrice coordinatrice
FR Abbr. IP
German Hauptprüfer / Hauptprüferin / Leitender Prüfer / Leitende Prüferin / Koordinierender Prüfer / Koordinierende Prüferin
DE Abbr. HP

References

 ScopeDocument partLanguageDocument
DEU AMG - Arzneimittelgesetz 19-Jul-2023 § 4 Absatz 25HM§ 4 Absatz 25DEDEU AMG - Arzneimittelgesetz 19-Jul-2023
DEU MPDG - Medizinprodukterecht-Durchführungsgesetz 28-Jun-2022 § 3 Absatz 5 – 6MD§ 3 Absatz 5 – 6DEDEU MPDG - Medizinprodukterecht-Durchführungsgesetz 28-Jun-2022
DEU MPDG - Medizinprodukterecht-Durchführungsgesetz 28-Jun-2022 § 30-001MD§ 30DEDEU MPDG - Medizinprodukterecht-Durchführungsgesetz 28-Jun-2022
DEU MPDG - Medizinprodukterecht-Durchführungsgesetz 28-Jun-2022 § 30-002MD§ 30DEDEU MPDG - Medizinprodukterecht-Durchführungsgesetz 28-Jun-2022
DEU MPDG - Medizinprodukterecht-Durchführungsgesetz 28-Jun-2022 § 62-001MD§ 62DEDEU MPDG - Medizinprodukterecht-Durchführungsgesetz 28-Jun-2022
DEU MPDG - Medizinprodukterecht-Durchführungsgesetz 28-Jun-2022 § 62-002MD§ 62DEDEU MPDG - Medizinprodukterecht-Durchführungsgesetz 28-Jun-2022
DEU MPDG - Medizinprodukterecht-Durchführungsgesetz 28-Jun-2022 § 62-003MD§ 62DEDEU MPDG - Medizinprodukterecht-Durchführungsgesetz 28-Jun-2022
EU EMA/698382/2021 - Guideline for the notification of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol 2021 6.4G6.4ENEU EMA/698382/2021 - Guideline for the notification of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol 2021
GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Article 14HMArticle 14ENGBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004
GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Article 16HMArticle 16ENGBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004
GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Article 2 (1)HMArticle 2 (1)ENGBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004
ICH ICH E6 Guideline R3 (2025) GLOSSARY - InvestigatorGGLOSSARY - InvestigatorENICH ICH E6 Guideline R3 (2025)
ISO ISO 14155 - Clinical investigation of medical devices for human subjects 2020 10.1MD10.1ENISO ISO 14155 - Clinical investigation of medical devices for human subjects 2020
ISO ISO 14155 - Clinical investigation of medical devices for human subjects 2020 10.2MD10.2ENISO ISO 14155 - Clinical investigation of medical devices for human subjects 2020
ISO ISO 14155 - Clinical investigation of medical devices for human subjects 2020 10.7MD10.7ENISO ISO 14155 - Clinical investigation of medical devices for human subjects 2020
ISO ISO 14155 - Clinical investigation of medical devices for human subjects 2020 10.8MD10.8ENISO ISO 14155 - Clinical investigation of medical devices for human subjects 2020
USA NCI GUIDELINES FOR INVESTIGATORS: ADVERSE EVENT REPORTING REQUIREMENTS FOR DCTD (CTEP AND CIP) INDs AND IDEs 30-Aug-2024 1.3G1.3ENUSA NCI GUIDELINES FOR INVESTIGATORS: ADVERSE EVENT REPORTING REQUIREMENTS FOR DCTD (CTEP AND CIP) INDs AND IDEs 30-Aug-2024
WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 Glossary - principal investigatorHMGlossary - principal investigatorENWHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995